Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) today announced financial results for the three months ended December 31, 2013 (“Second Quarter 2014”).
Fiscal Second Quarter and Recent Highlights
•The Company completed cohort 3 of its Phase 1b/2a clinical trial for its drug candidate, SNS01-T, for the treatment of multiple myeloma and lymphoma.
Help employers find you! Check out all the jobs and post your resume.
